Development of safe and rapid reporter viruses for studying pathogenic and pandemic viruses

Ended Project Grant Awarded Last action

Award ID
R43AI186556
Recipient
Awarding agency
Obligated
$865,545

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date
Place of performance
Philadelphia, PA 19104, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Neutralizing titer is a demonstrated correlate of protection across most viral pathogens. The traditional assay to assess neutralization titer is the plaque reduction neutralization test (prnt), which is generally regarded as slow, subjective, and variable. To conduct large scale clinical vaccine trials, thousands of serum samples from vaccinated individuals are typically assessed in neutralization assays, a scale that is difficult to achieve using live virus in high containment facilities. Optical reporters such as GFP and luciferase encoded in 'reporter viruses' are an alternative to prnt and are more streamlined, safe, and scalable than prnt assays but still require a week of experimentation. Here we propose to develop a rapid reporter virus (RRV) to assess virus infection and neutralization rapidly and safely. The development of this novel assay is in direct response to our customers' requests for a better neutralization readout.

Transactions

Action Obligated Date
Amendment $0
Amendment $288,515
Amendment $288,515
Original award $288,515

Quick answers

Who received award R43AI186556?

R43AI186556 was awarded to Integral Molecular Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 1, 2024.

How much is award R43AI186556 worth?

$865,545 has been obligated on R43AI186556.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login